display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced hepatocellular cancer (mHCC)
mHCC - 2nd line (L2)
immune chekpoint inhibitors
anti-PD-(L)1
pembrolizumab based treatment KEYNOTE-394
pembrolizumab alone KEYNOTE-240

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons